Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0242339 (
dyslipidemia
)
13,927
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Arteriosclerotic cardiovascular disease (ASCVD) is one of the major causes of death worldwide and most commonly develops as a result of atherosclerosis (AS). As we all know,
dyslipidemia
is a leading pathogenic risk factor for ASCVD, which leads to cardiac ischemic injury and myocardial infarction.
Dyslipidemias
include hypercholesterolemia, hypertriglyceridemia, increased low-density lipoprotein cholesterol (LDL-c) and decreased high density lipoproteins cholesterol (HDL-c). Mutations of
dyslipidemia
related genes have been proved to be the crucial contributor to the development of AS and ASCVD. In this study, a Han-Chinese family with ASCVD was enrolled and the lipid testing discovered an obvious reduced levels of HDL-c in the affected members. We then performed whole exome sequencing to detect the candidate genes of the family. After data filtering, a novel heterozygous nonsense mutation (NM_007168: c.3460C>T; p.R1154X) of
ABCA8
was detected and validated to be co-separated in the family members by Sanger sequencing. Previous studies have proved that deleterious heterozygous
ABCA8
variants may disrupt cholesterol efflux and reduce HDL-c levels in humans and mice. This study may be the second report related to
ABCA8
mutations in patients with reduced levels of HDL-c. Our study not only contributed to the genetic counseling and prenatal genetic diagnosis of patients with ASCVD caused by reduced HDL-c levels, but also provided a new sight among
ABCA8
, cholesterol efflux and HDL-c levels.
...
PMID:A Novel Nonsense Mutation of
ABCA8
in a Han-Chinese Family With ASCVD Leads to the Reduction of HDL-c Levels. 3276 Apr 29